Pay in 4 interest-free payments of $21.25 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
DMH-1 effectively inhibits the bone morphogenic protein (BMP) ALK2 receptor (IC50 = 108 nM)
TBK1controlPROTAC4
Rosenberg E
which was discovered by a team led by Koen Andries at Janssen Pharmaceutica
Besifloxacin Hydrochloride - CAS# 405165-61-9 B-PS DMH-1 effectively inhibits the boneBesifloxacin is a fourth generation fluoroquinolone antibiotic. The marketed compound is besifloxacin hydrochloride. It was developed by SSP Co. Ltd., Japan, and designated SS734. SSP licensed U. S. and European rights to SS734 for ophthalmic use to InSite Vision Incorporated (OTCBB: INSV) in 2000. InSite Vision developed an eye drop formulation (ISV 403) and conducted preliminary clinical trials before selling the product and all rights to Bausch &
US$ 12.00
US$ 3500.00